Get the Stockscreener App
2.06
0.98%
0.02
Seastar Medical Holding Corp stock is traded at $2.06, with a volume of 202.77K.
It is up +0.98% in the last 24 hours and down -4.19% over the past month.
SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses.
See More
Previous Close:
$2.04
Open:
$2.01
24h Volume:
202.77K
Relative Volume:
1.04
Market Cap:
$9.19M
Revenue:
-
Net Income/Loss:
$-26.23M
P/E Ratio:
-2.2556
EPS:
-0.9133
Net Cash Flow:
$-10.29M
1W Performance:
+3.52%
1M Performance:
-4.19%
6M Performance:
-60.98%
1Y Performance:
-82.04%
1-Day Range:
$2.01
$2.10
1-Week Range:
$1.6946
$2.10
52-Week Range:
$1.6946
$42.92
Seastar Medical Holding Corp Stock (ICU) Company Profile
Name
Seastar Medical Holding Corp
Sector
Industry
Phone
844-427-8100
Address
3513 BRIGHTON BLVD, DENVER
Compare ICU with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ICU
Seastar Medical Holding Corp
|
2.06 | 9.19M | 0 | -26.23M | -10.29M | -1.2274 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Seastar Medical Holding Corp Stock (ICU) Latest News
SEASTAR ALERT: Bragar Eagel & Squire, P.C. is Investigating - GlobeNewswire
ICU stock hits 52-week low at $1.82 amid market challenges - Investing.com
Medical Device Co. Brass Hid SPAC's True Value, Suit Says - Law360
SeaStar Medical Projects Multibillion-Dollar Market - GlobeNewswire
SeaStar Medical to Hold Business Update Conference Call on December 11, 2024 - GlobeNewswire
SeaStar Medical (ICU) to Host Key Business Update Call on December 11 - StockTitan
SeaStar Medical Activates Sentara Norfolk General Hospital and Provides Enrollment Update in Adult AKI Pivotal Trial - GlobeNewswire
SeaStar Medical Provides Updates on Enrollment of Adult Pivotal Clinical Study and Commercial Launch of Quelimmune - Investing.com Nigeria
SeaStar Medical (NASDAQ:ICU) Trading Down 1.6% – What’s Next? - Defense World
SeaStar Medical reduces authorized shares By Investing.com - Investing.com Canada
SeaStar Medical reduces authorized shares - Investing.com
SeaStar Medical to Present at Noble Capital Markets’ NobleCon20 on December 4, 2024 - GlobeNewswire
SeaStar Medical to Present at NobleCon20 Conference on Hyperinflammation Solutions | ICU Stock News - StockTitan
Leading Independent Proxy Advisory Firms ISS and Glass - GlobeNewswire
Leading Independent Proxy Advisory Firms ISS and Glass Lewis Support SeaStar Medical's Proposals to Ratify the Issuance of Shares and to Reduce the Number of Authorized Shares - Quantisnow
SeaStar Medical chief medical officer purchases $8,457 in stock By Investing.com - Investing.com Australia
SeaStar Medical chief medical officer purchases $8,457 in stock - Investing.com
Seastar Soars On Latest Tidings - MENAFN.COM
SeaStar Soars on Latest Tidings - Baystreet.ca
SeaStar Medical Reaches Milestone of 100th QUELIMMUNE Commercial Device as Shipments Begin to its Third Hospital Customer - Yahoo Finance
SeaStar Medical reports net revenue of USD 67,500 in Q3 2024 - Medical Buyer
SeaStar Medical Reports Third Quarter 2024 Financial Results and Provides a Business Update - Yahoo Finance
Half of Patients Now Enrolled in SeaStar Medical’s NEUTRALIZE-AKI Trial - MPO-mag
Critical Analysis: Merit Medical Systems (NASDAQ:MMSI) and SeaStar Medical (NASDAQ:ICU) - Defense World
SeaStar Medical (NASDAQ:ICU) Trading Down 3% – Here’s What Happened - Defense World
FDA grants breakthrough status to SeaStar Medical's SCD - Investing.com
FDA Grants Breakthrough Device Designation for SeaStar - GlobeNewswire
FDA Grants Breakthrough Device Designation for SeaStar Medical’s Selective Cytopheretic Device for Adults Undergoing Chronic Dialysis - Yahoo Finance
Record Monthly Enrollment Achieved in SeaStar Medical’s Pivotal Adult AKI Trial - GlobeNewswire
SeaStar Medical Adds Second Hospital Customer for QUELIMMUNE - Yahoo Finance
ICUSeaStar Medical Holding Corporation Latest Stock News & Market Updates - StockTitan
Economic Analysis Supporting Significant Hospitalization Cost Reduction with SeaStar Medical’s QUELIMMUNE Pediatric Therapeutic Device Presented at ASN Kidney Week 2024Update - Yahoo Finance
SeaStar Medical Announces that Stanford Medicine is Cleared - GlobeNewswire
Nuwellis ends SeaStar distribution and supply agreements - Investing.com
Seastar Medical settles dispute with Nuwellis for $900K - Investing.com
Seastar Medical settles dispute with Nuwellis for $900K By Investing.com - Investing.com UK
SeaStar Medical to Distribute QUELIMMUNE Directly to Hospital Customers - GlobeNewswire
SeaStar Medical's NEUTRALIZE-AKI trial surpasses halfway mark - Investing.com
SeaStar Medical's NEUTRALIZE-AKI trial surpasses halfway mark By Investing.com - Investing.com South Africa
SeaStar Medical Announces that Enrollment in its Adult Acute Kidney Injury Pivotal Trial Has Exceeded the Halfway Point Toward an Interim Analysis - GlobeNewswire
SeaStar Medical to Showcase New Mechanistic Data - GlobeNewswire
SeaStar Medical to Present at the 2024 Maxim Healthcare Virtual Summit - GlobeNewswire
SeaStar Medical expands trial sites for kidney injury device - Investing.com
SeaStar Medical Expands NEUTRALIZE-AKI Pivotal Trial Adding Two Premier Military Medical Facilities - GlobeNewswire
SeaStar medical executive buys $4.3k in company stock By Investing.com - Investing.com Australia
SeaStar medical executive buys $4.3k in company stock - Investing.com
SeaStar Medical Reports Enrollment Momentum in Its Pivotal Adult AKI Trial - GlobeNewswire
Seastar Medical Holding Corp Stock (ICU) Financials Data
Revenue
Net Income
Cash Flow
EPS
Seastar Medical Holding Corp Stock (ICU) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Chung Kevin | Chief Medical Officer |
Sep 30 '24 |
Buy |
4.26 |
1,000 |
4,258 |
9,435 |
2.88%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):